OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Biosimilars in IBD: What Every Clinician Needs to Know
Anthony Angyal, Shubha Bhat
Current Gastroenterology Reports (2024) Vol. 26, Iss. 3, pp. 77-85
Closed Access | Times Cited: 6
Anthony Angyal, Shubha Bhat
Current Gastroenterology Reports (2024) Vol. 26, Iss. 3, pp. 77-85
Closed Access | Times Cited: 6
Showing 6 citing articles:
Biobetters and biosimilars in Inflammatory Bowel Disease
Jacopo Fanizza, Ilaria Faggiani, Mariangela Allocca, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101992-101992
Closed Access
Jacopo Fanizza, Ilaria Faggiani, Mariangela Allocca, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101992-101992
Closed Access
Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern
Paulina Suo, Ashish Srinivasan, Lena Thin, et al.
Journal of Gastroenterology and Hepatology (2025)
Open Access
Paulina Suo, Ashish Srinivasan, Lena Thin, et al.
Journal of Gastroenterology and Hepatology (2025)
Open Access
Healthcare Access for Patients With Inflammatory Bowel Disease in the United States: A Survey by the Crohn’s & Colitis Foundation
Ariel Jordan, Shubha Bhat, Tauseef Ali, et al.
Inflammatory Bowel Diseases (2024)
Open Access | Times Cited: 1
Ariel Jordan, Shubha Bhat, Tauseef Ali, et al.
Inflammatory Bowel Diseases (2024)
Open Access | Times Cited: 1
Monoclonal Antibody Risankizumab for Ulcerative Colitis
Gilaad G. Kaplan
JAMA (2024) Vol. 332, Iss. 11, pp. 877-877
Closed Access | Times Cited: 1
Gilaad G. Kaplan
JAMA (2024) Vol. 332, Iss. 11, pp. 877-877
Closed Access | Times Cited: 1
Efficacy, Safety and Persistence on Therapy after Non-medical Switching from Originator Adalimumab in IBD-Real Life Experience from Two Tertiary Centres
Popescu Remus, Teodora SPATARU, Monica State, et al.
(2024)
Open Access | Times Cited: 1
Popescu Remus, Teodora SPATARU, Monica State, et al.
(2024)
Open Access | Times Cited: 1
The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres
Teodora SPATARU, Remus Popescu, Monica State, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1319-1319
Open Access | Times Cited: 1
Teodora SPATARU, Remus Popescu, Monica State, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1319-1319
Open Access | Times Cited: 1
Shot heard around the world? Subcutaneous Infliximab (CT-P13) as Maintenance Therapy for Inflammatory Bowel Disease
Catalina Mulanax, Fernando Velayos
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 841-842
Closed Access
Catalina Mulanax, Fernando Velayos
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 841-842
Closed Access
